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Abstract. The aim of this study was to investigate the inﬂuence of experimental conditions on
levothyroxine sodium release from two immediate-release tablet formulations which narrowly passed the
standard requirements for bioequivalence studies. The in vivo study was conducted as randomised, single-
dose, two-way cross-over pharmacokinetic study in 24 healthy subjects. The in vitro study was performed
using various dissolutionmedia, and obtained dissolution proﬁles were compared using the similarity factor
value. Drug solubility in different media was also determined. The in vivo results showed narrowly passing
bioequivalence. Considering that levothyroxine sodium is classiﬁed as Class III drug according to the
Biopharmaceutics Classiﬁcation System, drug bioavailability will be less sensitive to the variation in its
dissolution characteristics and it can be assumed that the differences observed in vitro in some of
investigated media probably do not have signiﬁcant inﬂuence on the absorption process, as long as rapid
and complete dissolution exists. The study results indicate that the current regulatory criteria for the value
of similarity factor in comparative dissolution testing, as well as request for very rapid dissolution (more
than 85% of drug dissolved in 15 min), are very restricted for immediate-release dosage forms containing
highly soluble drug substance and need further investigation. The obtained results also add to the existing
debate on the appropriateness of the current bioequivalence standards for levothyroxine sodium products.
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INTRODUCTION
Levothyroxine sodium (L-Na) is a drug used as the
replacement therapy in primary hypothyroidism (1). It is
commercially available from a number of sources, but ther-
apeutic equivalence and interchangeability of various brands
remain questionable even if bioequivalence is proven (2). One
of the main obstacles for determining L-Na products bioequi-
valence is that exogenous levothyroxine cannot be distin-
guished from the endogenously produced hormone. Current
European Medicines Agency guideline for drug bioequiva-
lence studies states that for endogenous substances, the
sampling schedule should allow characterization of the endog-
enous baseline proﬁle for each subject in each period (3).
Often, a baseline is determined from two to three samples
taken before the drug products are administered. The phar-
macokinetic evaluation should be performed using baseline
correction so that the calculated pharmacokinetic parameters
refer to the additional concentrations provided by the treat-
ment. Administration of supra-therapeutic doses can be
considered in bioequivalence studies of endogenous drugs,
provided that the dose is well tolerated, so that the exogenous
concentrations over baseline provided by the treatment may
be reliably determined. Rarely, baseline correction may not be
needed if substantial increases over baseline endogenous
levels are obtained (4). The Food and Drug Administration
(FDA) issued the guidance for in vivo pharmacokinetic and
bioavailability studies and in vitro dissolution testing of L-Na
tablets in 2000 (5). However, the adequacy of the proposed
bioequivalence standards for levothyroxine products has been
discussed in a number of reports (6–8). The limitations refer to
the fact that: (1) levothyroxine is endogenous substance and
the administered drug is not the only source of the hormone
measured; (2) its concentration is regulated by the dynamic
feedback system via the hypothalamic–pituitary–thyroid gland
axis; (3) lack of sensitivity of the analytical techniques available
and (4) the need for high dose administration associated with
the inherent risk for the development of adverse reactions.
There are also reports indicating that therapeutic
inequivalence of L-Na products resulted from an inadequate
drug content and/or dissolution from the dosage form; it has
been observed that the therapeutic failures resulting from
the generic levothyroxine product administration were
caused by its content being 25–30% less than that of
labelled drug (9–11). Being an extremely low-dose drug,
levothyroxine tablets were reported to exhibit lot-to-lot
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content variability because of poor homogenisation. Con-
sequently, a more tightened potency range has been recently
approved by the FDA (12).
L-Na is an amphoteric molecule with three pKa values:
2.2, 6.7 and 10.1 (13). Solubility of L-Na is pH dependent, and
the reported solubility of L-Na in water at 25°C is 0.15 mg/mL
(14,15). There are no literature data for the pH-solubility
proﬁle of L-Na at 37°C in aqueous media important for the
Biopharmaceutics Classiﬁcation System (BCS) class determi-
nation, but it can be found in several works that L-Na is
classiﬁed as Class III—high-solubility and low-permeability
drug (16,17). In accordance with the concept of the BCS,
there are regulatory guidelines recommending that in certain
situations, similarity of in vitro dissolution proﬁles demon-
strated in three different pH media could be used as the in
vitro surrogate for the in vivo bioequivalence testing of BCS
Class I and Class III drugs (3,18,19). Thus, the use of reliable
and discriminatory dissolution test is of major importance.
Interestingly, shortly after the revision of bioequivalence
requirements, also the United States Pharmacopoeia (USP)
dissolution speciﬁcation for levothyroxine sodium tablets was
revised in 2002: previously used USP phosphate buffer pH 7.4
was substituted by 0.01MHClwith 0.2% sodium lauryl sulphate
(SLS), and the recommended paddle rotation speed was altered
from 100 to 50 rpm (20,21). The USP 32 gives more ﬂexible
recommendations involving the use of both 50 and/or 75 rpm
paddle speed, 0.01 M HCl with or without surfactant and either
500 or 900 mL media, depending on the drug dosage (22).
The aim of the present study was to evaluate the effect of
various experimental conditions on levothyroxine release from
two drug products which passed the standard requirements for
the bioequivalence study. In order to give an improvement in
the biopharmaceutical characterization of this drug, the pH-
solubility proﬁle of L-Na at 37°C, obtained in aqueous media
over the pH range of 1.2–7.4 is also presented in this study.
MATERIALS AND METHODS
Materials
Two immediate-release tablet formulations, containing
100 μg of L-Na, were evaluated throughout the study. Test
formulation was Tivoral® tablets (Galenika ad., Serbia, batch
2696, expiry date September 2011) and the reference
formulation was Euthyrox® tablets (Merck, Germany, batch
5543502, expiry date December 2010). L-Na drug substance
was obtained from Peptido GmbH, Germany.
Drug release media and buffers for solubility determi-
nation were prepared using potassium chloride (JT Baker,
The Netherlands), hydrochloric acid (Merck), glacial acetic
acid (Merck), potassium dihydrogenphosphate (JT Baker),
sodium acetate (JT Baker), sodium hydroxide (Merck) and
sodium lauryl sulphate (Sigma, USA). All chemicals used in
HPLC analysis were analytical or HPLC reagent grade.
In Vivo Study
Patients and Study Design
The in vivo study was designed as an open-label,
randomised, single-dose, two-way cross-over bioequivalence
study performed on 24 healthy subjects of both genders. A
total of 22 subjects completed the study. Their ages ranged
from 24 to 56 years (33.33±9.70; mean±SD) and their body
mass index from 19.53 to 33.46 kg/m2 (24.59±3.73; mean±
SD). Two subjects decided not to continue the study due to
headache just after the drug administration in the ﬁrst period
of the study. The study was performed in accordance with the
principles enunciated in the Declaration of Helsinki
(Edinburgh 2000) and the ICH harmonised tripartite
guideline regarding Good Clinical Practice (23). The
protocol was approved by the Ethics Review Board. All
subjects gave consent to participate in the study by signing the
informed consent form. In each period of the study, subjects
were housed from the 12-h pre-drug administration till the
12-h blood sampling. The reference and the test drugs were
given in a single oral dose of 600 μg (six 100 μg tablets),
according to the randomization list, with the washout period
of 35 days. The tablets were given under fasting conditions,
orally, with 240 mL of water. Blood samples were taken at
the following intervals: 30 min, 15 min and immediately
before dosing, 0.33, 0.67, 1, 1.33, 1.67, 2, 2.5, 3, 4, 6, 9, 12, 24
and 48 h after dosing.
Analytical Method
The serum concentrations of levothyroxine and triiodo-
thyronine were determined through the use of commercial
chemiluminescent competitive immunoassay (Immulite 2000
Total T4 and Immulite 2000 Total T3, Siemens Medical
Solutions Diagnostics, Los Angeles, CA, USA). The calibra-
tion ranges for the measurement of levothyroxine and
triiodothyronine were 10 to 240 ng/mL and 0.4 to 6.0 ng/mL,
respectively. The intra-assay coefﬁcients of variation (CVs) for
two levothyroxine quality control samples (theoretical con-
centration of 82.4 and 124 ng/mL) were 4.2% and 8.0%,
respectively. The corresponding inter-assay CVs were 5.0%
and 5.5%. The intra-assay CVs for two triiodothyronine
quality control samples (theoretical concentration of 1.6 and
3.4 ng/mL) were 4.9% and 5.3%, respectively, while the inter-
assay CVs were 5.6% and 6.9%. The analytical sensitivity for
levothyroxine was 3.0 ng/mL and for triiodothyronine was
0.2 ng/mL.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic analysis was performed according to
the requirements for bioequivalence studies (3). Differences
between the obtained and the pre-dose concentrations (the
average value of the ﬁrst three samples) for each subject,
sampling time and formulation were used as a basis for the
calculations of the main pharmacokinetic parameters and
statistical analysis. As the level of levothyroxine started to
rise in about half of the subjects as a consequence of the
physiological response, the time limit for the analysis was 9 h
post-administration. The following parameters were derived
from the serum concentrations time proﬁles: the area under
the serum concentration vs. time curve up to sampling time
(AUC0–t), the area under the serum concentration vs. time
curve to inﬁnity (AUC0–∞), the maximum serum concentra-
tion (Cmax), the time at which the maximum serum concen-
tration is attained (Tmax), the half time of elimination (T1/2)
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and the elimination rate constant (Kel). The Cmax and Tmax
were determined from the concentration–time proﬁle. The
AUC0–t was calculated using the trapezoidal rule from point 0
up to 9 h. The AUC0–∞ was calculated from the equation:
AUC0–∞=AUC0–t+Cn/Kel, where Cn is the last serum sample
concentration, and T1/2 was calculated from the equation
T1/2=ln2/Kel. The bioavailability comparison was carried
out on AUC0–t, AUC0–∞ and Cmax (primary pharmacokinetic
parameters). The bioequivalence acceptance interval was set to
80–125% as justiﬁed in the protocol of the study. The 90%
conﬁdence intervals (CI) for the ratio between drug formula-
tions least squares means were derived from the analyses of the
log-transformed parameters AUC0–t, AUC0–∞ and Cmax. All
pharmacokinetic and statistical analyses were performed using
the EquivTest 2.0 statistical programme.
Solubility Measurement
The solubility of L-Na was determined in USP hydrochloric
acid buffer pH 1.2, USP acetate buffers pH 4.5 and pH 5.5 and
USP phosphate buffers pH 6.8 and pH 7.4. An excess of L-Na
drug substancewas added into 10mLof themedium in glass vials.
The sealed vials were shaken continuously for 24 h in shaking
water bath (Haake, Germany) at 37±1°C and then stored for a
further 24 h without agitation. In each case, sediment on the
bottom of the vial was observed and separated by centrifugation.
The supernatants were ﬁltered through the glass microﬁber ﬁlters
(Macherey-Nagel, Germany). The L-Na concentration in the
saturated solution was determined by HPLC analysis.
In Vitro Study
The dissolution tests were performed with both test and
reference formulations that had been used in the bioequiva-
lence study. The studies were conducted using rotating paddle
and rotating basket method (Erweka DT 80, Germany). The
following media were used: USP hydrochloric acid buffer
pH 1.2, USP acetate buffer pH 4.5 and USP phosphate buffer
pH 6.8. The medium volume used was 500 mL. The rotating
speed was 100 rpm in the rotating basket apparatus, 50 rpm
and 75 rpm in the rotating paddle apparatus. The inﬂuence of
agitation intensity was tested in pH 6.8 dissolution medium.
The dissolution tests were also carried out according to the
USP 32 monograph for L-Na tablets (22), with 50 rpm rotating
paddle apparatus and 500 mL of 0.01 M HCl with 0.2% SLS
and according to the USP 24 monograph for L-Na tablets (20),
with 100 rpm rotating paddle apparatus and 500 mL of
phosphate buffer pH 7.4. All tests were performed with 12
tablets of each formulation, and the results presented here are
their mean values. The 15.0-mL aliquots were withdrawn at 10,
15, 20, 30, 45 and 60 min from the beginning of the tests and
replaced with the same volume of the fresh medium.
Analytical Method
The percent of L-Na dissolved in samples was deter-
mined by HPLC analysis with an HP1100 chromatograph
(Agilent Technologies, Palo Alto, CA, USA) equipped with
HP1100 binary pump, UV–visible detector and autosampler.
Data were acquired with Agilent Chemstation software. The
determinations were done on Zorbax SB-C18 analytical
column (250×4.6 mm, macropore size 5 μm). The mobile
phase was a mixture of 0.34% (m/v) tetrabutylammonium
hydrogen sulphate aqueous solution and acetonitrile, starting
with 35% of acetonitrile for the ﬁrst 10 min and with the ﬂow
rate 1.0 mL/min and then increasing acetonitrile level to 70%
till the end of analysis. The wavelength of the detector was set
to 225 nm. The injection volume was 100 μL. The method was
linear over L-Na concentration range of 0.10–0.31 μg/mL, and
the coefﬁcient of correlation was 0.995%. RSD values for
intra-day and for inter-day precision were less than 2%.
The L-Na release proﬁles obtained in vitro in various test
conditions were compared according to the similarity factor
value (f2) (24).
RESULTS
In Vivo Study
The mean values of the levothyroxine serum concen-
tration in blood samples taken 30 min, 15 min and immedi-
ately before drug administration were considered in the study
as pre-dose level of levothyroxine (Fig. 1). Mean levothyrox-
ine serum concentrations vs. time without adjustment for
baseline levels of endogenous levothyroxine are shown in
Fig. 2, while individual levothyroxine concentrations with
Fig. 1. The pre-dose level of levothyroxine in subjects before administration of the test formulation
(grey bar) and the reference formulation (white bar). Data are mean±SD (n=3)
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baseline correction can be seen in Fig. 3. Table I shows
levothyroxine pharmacokinetic parameters after administration
of the test and the reference formulations. Calculation of
pharmacokinetic parameters and statistical analysis were per-
formed using values obtained as difference between the
obtained concentration of levothyroxine at the time point and
pre-dose level of levothyroxine, due to the reason that the
measured level was the result of sum of endogenous and
exogenous levothyroxine levels. The calculations of the log-
transformed data of the main pharmacokinetic parameters
AUC0–t, AUC0–∞ and Cmax, as well as statistical testing of the
differences between them according to analysis of variance test
(ANOVA), showed that there were no signiﬁcant differences in
those parameters (Table II). The study also showed no differ-
ences in concentrations of triiodothyronine after administration
of levothyroxine (Fig. 4); the maximum triiodothyronine levels
obtained after administration of the test and the reference
formulations were 1.86±0.24 and 1.87±0.22 ng/mL, respectively.
Solubility Studies
The drug equilibrium solubility results (Table III) indi-
cate that L-Na solubility decreases with an increase in pH,
goes through a minimum at around pH 4–5 and increases
again with further increase in pH. The dose/solubility ratios,
calculated using solubility value at each pH for the three
Fig. 2. Mean levothyroxine concentration (±SD)–time proﬁles after administration of six
100-μg tablets of the test and the reference formulations uncorrected for endogenous
levothyroxine baseline level
Fig. 3. Individual levothyroxine concentration–time proﬁles, corrected for the endogenous
levothyroxine baseline level: a after the test drug administration and b after the reference
drug administration
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doses of L-Na, show that L-Na fails to meet the dose/
solubility ratio criterion of below 250 ml for drug substance
to be classiﬁed as highly soluble only for the 600 μg dose
between pH 4.5 and pH 6.8 (3,18).
In Vitro Study
The dissolution proﬁles of the investigated formulations
obtained under various experimental conditions are pre-
sented in Fig. 5a, b. For both drug formulations, the fastest
dissolution was obtained in pH 1.2 medium, using the rotating
paddle apparatus at 75 rpm. The slowest drug dissolution was
observed in the phosphate buffer pH 6.8, using the rotating
paddle apparatus at 50 rpm. Comparative dissolution data for
the test and the reference formulations in media with different
pH values, as well as under the compendially recommended
experimental conditions given in the USP 24 (old method) and
in the USP 32 (new method), are given in Figs. 6 and 7.
Relevant similarity factor (f2) values are given in Table IV.
DISCUSSION
In Vivo Study
This bioequivalence study was conducted in accordance
with the current bioequivalence guidelines (3,5). After oral
administration of both formulations under fasting conditions,
levothyroxine underwent rapid absorption from the gastro-
intestinal tract. The highest concentration both for the test
and the reference formulations was observed in the majority
of subjects 1.66 h after administration. The activation of the
strong physiological feedback system which regulates the
secretion of the endogenous levothyroxine was seen about 9 h
after drug administration: levothyroxine values began to rise.
Therefore, in the pharmacokinetic and statistical analysis,
only ﬁrst 9 h was taken into account because only during this
time period, the levels of levothyroxine corresponded to the
administered formulation (Fig. 3). The serum concentrations
of triiodothyronine, the main active metabolite of levothyr-
oxine (25), after administration of the test formulation were
comparable to those obtained after administration of the
reference product and did not show signiﬁcant statistical
differences. Taking into consideration the baseline level of
levothyroxine in the pharmacokinetic and statistical analysis
and correcting the observed values with its pre-dose level are
discussed by many authors (4,6,26). The endogenous levels of
levothyroxine in our subjects were variable and higher than
presented in the bioequivalence study of Di Girolamo et al.
(26). The closer the baseline level to the total concentration
of levothyroxine, the greater its inﬂuence on the estimation of
bioequivalence. The relatively high baseline level of levothyr-
oxine observed in our study could cover the differences
between studied formulations, so correcting for baseline
improved the sensitivity of bioequivalence assessment. Even-
tually, it might be possible to explore by means of population
pharmacokinetics the inﬂuence of the baseline level of
levothyroxine on the kinetic parameters in order to choose
subjects with lower, but still physiological, endogenous levels.
This will also result with fewer adverse reactions. The FDA-
recommended dose of 600 μg for levothyroxine bioequiva-
lence studies is much higher than therapeutic dose, but it is
recommended due to the opinion that lower doses, with
relatively high baseline levels, result in greater variation and
difﬁculties in proving bioequivalence (4). The observed Cmax
values in our study were similar to those presented in other
bioequivalence studies for L-Na tablets (26,27). The 90% CI
for the log-transformed main pharmacokinetic parameters
passed the standard requirements for bioequivalence studies,
but it was on the lower limit of acceptability for AUC0–t and
AUC0–∞. The bioequivalence was demonstrated in 22 healthy
subjects (two subjects did not complete the study), which is
in accordance with the previously published report by Dong
Table I. Descriptive Statistical Analysis of the Pharmacokinetic Parameters for the Test and the Reference Formulations
Parameter
Test formulation Reference formulation
±SD CV (%) ±SD CV (%)
AUC0–t (ngh/mL) 140±64.6 (40.5–271) 46.2 145±58.9 (64.7–265) 40.6
AUC0–∞ (ngh/mL) 188±103 (42.4–422) 54.5 194±95.8 (66.6–372) 49.4
Cmax (ng/mL) 33.2±9.17 (18.6–54.2) 27.6 36.2±6.95 (23.3–57.0) 26.6
Tmax (h) 1.96±0.820 (0.670–4.00) 41.8 1.99±1.18 (1.00–6.00) 59.1
Kel (1/h) 0.29±0.17 (0.10–0.70) 58.4 0.27±0.18 (0.10–0.72) 65.3
T1/2 (h) 3.12±1.49 (0.990–6.73) 47.6 3.44±1.66 (0.960–6.98) 48.3
AUC the area under the serum concentration vs. time curve, Cmax the maximum serum concentration, Tmax the time of maximum
concentration, Kel the elimination rate constant, T1/2 the half time of elimination, SD the standard deviation, CV the coefﬁcient of variation
Table II. The 90% Conﬁdence Intervals for the Levothyroxine Treatment
AUC0–t (ngh/mL) AUC0–∞ (ngh/mL) Cmax (ng/mL)
Point estimate 0.932 0.938 0.921
Lower limit 0.801 0.800 0.847
Upper limit 1.09 1.16 1.00
Bioequivalency BE BE BE
AUC the area under the serum concentration vs. time curve, Cmax the maximum serum concentration, BE bioequivalence
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et al., who also showed bioequivalence between generic and
brand-name L-Na products in a group of 22 euthyroid
individuals (28). Although the FDA deﬁnes L-Na as Narrow
Therapeutic Index (NTI) drug, the acceptance interval
remains the same like for non-NTI drugs and there is no
recommendation for its narrowing (5). The question of
levothyroxine being an NTI drug is controversial (29). In
the clinical practice, it is perceived as NTI drug. The
secretion of levothyroxine is precisely regulated through
the physiological feedback system, and it shows great
interindividual variability; the substitution therapy can easily
cause a problem and bring patient to hyperthyreotic or
hypothyreotic condition. That is why it must be correctly
dosed and monitored in order to achieve the positive
outcome. On the other hand, L-Na does not ﬁt the NTI
drug deﬁnition as a drug where the ratio of the lowest
concentration at which clinical toxicity occurs, to the median
concentration providing a therapeutic effect, is less than or
equal to 2 (30). The recommended use of such large dose in
the bioequivalence study, much larger than used clinically,
cannot be considered safe for one NTI drug. So, until the
controversy about L-Na designation as NTI drug is solved, the
standard criteria for bioequivalence assessment should be
used. It is obvious that a further research in the ﬁeld of design
of a study for investigating bioequivalence of L-Na formula-
tions needs to be done in the future. This standard average
bioequivalence method could be substituted with the scaled
average bioequivalence approach; the bioequivalence limits
could be adjusted by scaling to the within-subject variability of
the reference product in the study (31,32).
Solubility Studies
The drug equilibrium solubility of L-Na between pH 4.5
and 6.8 indicates that it does not meet the current BCS
criteria for high-solubility drug only for the 600-μg dose. Such
a large dose of L-Na, recommended for the use in the
bioequivalence studies for L-Na tablets, will never be used
clinically. The average full replacement dose of L-Na is 100–
150 μg/daily for adult person, and larger doses are seldom
required (25). For those doses, L-Na meets the criterion for
highly soluble drug.
In Vitro Study
The Influence of Experimental Conditions on Dissolution Test
Results
Due to the chemical structure of L-Na and the presence
of two acidic and one basic group, pH value can have an
impact on the solubility of this substance and, consequently,
on drug dissolution from tablets. Dissolution proﬁles obtained
in various pH media were indicative of this effect. The highest
dissolution rate and complete release was achieved in pH 1.2
medium for both the test and the reference formulations, with
more than 85% of L-Na dissolved for 15 min. In the acetate
buffer pH 4.5, the amounts of drug released were the lowest
for both formulations, due to the lower L-Na solubility in the
pH range 4–5. In the phosphate buffer pH 6.8, drug
dissolution increased, resulting in more than 85% of L-Na
Fig. 4. Mean triiodothyronine concentration (±SD)–time proﬁles after administration of
six 100-μg tablets of the test and the reference formulations
Table III. Solubility and Dose/Solubility Ratio at 37°C of the Three Strengths of Levothyroxine sodium in Different Media
pH Solubility (μg/ml)
Dose (μg)
100 150 600
Dose/solubility ratio
pH 1.2 7.10 14.1 21.1 84.5
pH 4.5 0.92 108.7 163.0 652.2
pH 5.5 0.94 106.4 159.6 638.3
pH 6.8 1.90 52.6 78.9 315.8
pH 7.4 2.80 35.7 53.6 214.3
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dissolved from both formulations in the time interval from 15
to 20 min. Differences between dissolution proﬁles obtained
in different media were notable at the early time points (i.e.
10 and 15 min).
The intensity of agitation and the nature of the stirrer
affect hydrodynamics of the complex dissolution system (33).
Low rotational speeds affect the reproducibility of the
hydrodynamics; on the other hand, high rotating speed may
cause turbulence. The inﬂuence of agitation intensity on drug
dissolution was particularly pronounced in the case of the
reference formulation where the lower rotating speeds
resulted in slow and incomplete drug dissolution. It can be
seen that dissolution proﬁles of the test formulation were
slightly faster than those of the reference and, in spite of
certain differences, less affected by the experimental con-
ditions applied (Fig. 5). In all investigated cases, L-Na
dissolution from the test formulation was rapid, resulting in
more than 85% dissolved in 30 min. Drug dissolution proﬁles
from the reference formulation were more diverse, indicating
that both media composition and agitation intensity may
inﬂuence. This is in accordance with the results reported by
Pabla et al. who showed that dissolution of the generic
formulation was less susceptible to the media pH when
compared to the reference drug (34).
Comparative Dissolution Testing
It is not unusual that dissolution test conditions and
requirements given in pharmacopoeias and regulatory guide-
lines are not adequate for estimating correlation between the
in vitro and in vivo drug behaviour. Some differences
observed in vitro may be over discriminatory and may not
reﬂect the in vivo drug availability; on the other side, some
tests may be under discriminatory and may hide important
facts. According to the current regulatory guidelines (3,18), in
certain cases, the in vitro dissolution testing might serve as a
surrogate for the in vivo bioequivalence studies if compara-
tive dissolution proﬁles gathered at three different pH values
are shown to be similar. In the present study, similarity of
dissolution proﬁles for the investigated formulations was
obtained in the pH 1.2 and pH 6.8 media. However, some
differences between the two formulations were observed
when dissolution testing was carried out in the acetate buffer
(pH 4.5), characterised by the similarity factor value of 45.2
(Table IV). The differences were more pronounced at the
early time points, with more than 85% of L-Na dissolved after
20 min in the case of the test formulation and after 30 min in
the case of the reference formulation. In all the investigated
cases, L-Na release was faster from the test formulation
(Fig. 6). The investigated formulations had different dissolu-
tion behaviour when dissolution testing was carried out under
the old USP conditions, too. The release of L-Na for both the
test and the reference formulations was greater in the 0.01 M
HCl with surfactant addition with the saturation level
achieved after 15–20 min. The use of pH 7.4 phosphate
buffer gave lower level of L-Na dissolved, with more than
85% of L-Na dissolved after 20–30 min in the case of the test
formulation and after 30 min in the case of the reference
Fig. 5. The inﬂuence of experimental conditions on L-Na dissolution from tablets: a test
formulation and b reference formulation. Data are mean±SD (n=12)
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formulation. The presence of surfactant in acidic dissolution
medium brought signiﬁcant increase in the percentage of L-Na
dissolved, which can be profoundly seen in the case of the
reference formulation. This is in accordance with the results
reported by Volpato et al. (35). The f2 value of 67.6 shows that
proﬁles obtained should be regarded as similar, while the same
formulations tested with the old USP method would be
described as dissimilar (Table IV).
Formulation factors certainly play an important role in
drug dissolution. The presence of a superdisintegrant in the
formulation can have a great impact on drug release from
solid dosage form. Crosscarmelose sodium is a type of
superdisintegrant, which is generally used in smaller concen-
trations than conventional disintegrants and it is present in
both the test and the reference formulations (36,37). It has
ﬁbrous nature and great ability to swell in contact with water,
causing rapid tablet disintegration. Crosscarmelose sodium is
probably responsible for good and rapid dissolution of L-Na
from the investigated formulations under suitable conditions.
The use of the same excipients in both formulations is in
accordance with the current regulatory recommendations that
the test and the reference formulations should be similar in
quality, and, as much as possible, in quantity (3). The in vivo
study showed that the test and the reference formulations
narrowly passed the standard requirements for bioequiva-
lence; the values of AUC0–t, AUC0–∞ and Cmax were slightly
lower for the test than for the reference formulation.
Dissolution studies were performed with single 100-μg tablet
units which represent the average therapeutic dose. The
similarity of dissolution proﬁles of studied formulations was
conﬁrmed in pH 1.2 and pH 6.8 media and in 0.01 M HCl
with 0.2% SLS. The use of the old USP method (phosphate
buffer pH 7.4) resulted in evident differences among the
release proﬁles obtained for the investigated formulations.
Fig. 6. Comparative dissolution data of the test and the reference formulations in: a
hydrochloric acid buffer pH 1.2, b acetate buffer pH 4.5 and c phosphate buffer pH 6.8.
Data are mean±SD (n=12)
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The release of L-Na from the reference formulation was
slower and more gradual than in the case of the test
formulation. The observed differences were more pro-
nounced at the early time points, but after 30 min, more than
85% of L-Na was dissolved from both formulations. The in
vitro drug product performance in various dissolution media
can reveal certain differences which are not reﬂected in vivo.
There are numerous reports demonstrating that drug for-
mulations with proven bioequivalence show signiﬁcant differ-
ences among the in vitro drug release proﬁles as measured by
the f2 values (35,38,39). In the study of Volpato et al. (35), the
old USP method demonstrated signiﬁcant differences
between the two L-Na formulations which were found to be
bioequivalent in vivo, while the proﬁles obtained using the
current USP method were almost superimposable. Based on
the literature data, L-Na belongs to the BCS Class III group
(16,17). Our solubility tests results show that L-Na meets the
criterion for highly soluble drug at the therapeutic doses and
fails to meet this criterion only for the dose used in the
bioequivalence study. L-Na presents very speciﬁc case of a
drug where bioequivalence of different tablet formulations is
determined with the test dose much larger than clinical doses
in order to reduce the impact of endogenous levothyroxine
level on the bioequivalence estimation. Such a large dose will
never be used clinically, so, in terms of therapeutic use, L-Na
can be regarded as highly soluble and, considering the data
on its oral absorption and permeability, it may ﬁt into BCS
class III, which is in accordance with the literature data. Thus,
the rate and extent of absorption of this drug are limited by
its permeability and not its solubility or dissolution rate,
providing that drug release is rapid and complete. It can be
expected that the solid dosage forms of BCS Class III active
substances will show the same in vivo behaviour like oral
solutions, for which bioavailability is considered self-evident
(40,41). Furthermore, there are several studies in the
literature reporting bioequivalence between levothyroxine
tablets and oral levothyroxine solution (42,43). The current
regulatory recommendations for very rapid dissolution (more
than 85% in 15 min) and the value of similarity factor greater
than 50 for the comparative dissolution testing might be too
restrictive for BCS Class III drugs (3). The critical f2 value of
50 is obtained from the similarity of dissolution proﬁles based
on the average difference of 10% at sampling time points
(44). The general question is how large could be the differ-
ence between the drug mean dissolution proﬁles before the
difference is likely to impact on the in vivo performance.
Fig. 7. Comparative dissolution data of the test and reference formulations in: a phosphate
buffer pH 7.4 at paddle rotation speed of 100 rpm (old USP method), b 0.01 M HCl with
0.2% SLS at paddle rotation speed of 50 rpm (actual USPmethod). Data are mean±SD (n=12)
Table IV. Similarity Factor Values
Media f2
pH 1.2 NA
pH 4.5 45.2
pH 6.8 66.6
USP 24 40.1
USP 32 67.6
f2 the similarity factor,NA not applicable (very rapid drug dissolution)
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Considering that L-Na is BCS Class III high-solubility and
low-permeability drug, it is probable that small differences
observed in the in vitro drug release do not have signiﬁcant
linkage to the in vivo performance, providing that drug
release is sufﬁciently rapid. Considering that all calculated f2
values were greater than 40, opportunity might therefore exist
to utilise less restrictive criteria in assessing the similarity
between formulations. Our results raise the debate on the
validity of using current f2 criteria for the comparative
dissolution testing of rapidly dissolving immediate-release
dosage forms. Substantial additional data will however need
to be gathered for a range of drugs and formulations before
the reality of this opportunity can truly be assessed.
CONCLUSION
The test formulation met the standard regulatory criteria
for bioequivalence to the reference formulation when the
bioequivalence study was conducted according to the current
guidelines, although the results narrowly passed bioequivalence
limits. On the in vitro side, both drug products exhibited rapid
drug dissolution under the majority of experimental conditions
studied. Drug dissolution from the test formulation was less
susceptible to the effect of experimental conditions when
compared to the reference formulation. The investigated drug
products were shown to be similar under the experimental
conditions currently recommended by the USP, as well as in the
pH 1.2 and pH 6.8 dissolution media, while the differences
between products were observed in the acetate buffer pH 4.5
and under the old USP experimental conditions. The results
obtained indicate that the current regulatory recommendations
for very rapid dissolution (more than 85% of drug dissolved in
15min) and the f2 value greater than 50may be too restrictive for
biowaiver application in the case of immediate-release dosage
forms containing highly soluble drug substance and need to be
additionally discussed. The results of this study also contribute to
the existing debate on the appropriateness of the current
bioequivalence standards for levothyroxine sodium products.
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